{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-332858","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2026-08-04T20:16:35+00:00","discovered_at":"2026-08-04T20:18:08.362044+00:00","generated_at":"2026-08-04T20:18:46.711755+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acadia Q2 revenue up 16% to $308M; raises FY2026 guidance to $1.24-1.30B","bullets":["DAYBUE net sales $125M (+30% YoY); NUPLAZID net sales $183M (+10% adj. YoY).","Full-year 2026 total revenue guidance raised to $1.24-1.30B; DAYBUE guidance raised to $480-510M.","Phase 2 remlifanserin topline results for Alzheimer's disease psychosis expected Sept-Oct 2026.","CHMP positive opinion for DAYBUE in EU for Rett syndrome; FDA Fast Track for remlifanserin.","CEO reaffirms long-term ambition of ~$1.7B annual net sales by 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-332858","json":"https://secwatch.observer/filing/0001193125-26-332858.json","markdown":"https://secwatch.observer/filing/0001193125-26-332858.md","text":"https://secwatch.observer/filing/0001193125-26-332858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526332858/0001193125-26-332858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526332858/acad-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:18:46.711755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}